Last Updated: November 16, 2026

Details for Patent: 9,951,043

« Back to Dashboard


Summary for Patent: 9,951,043
Title:Therapeutic compounds
Abstract:Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Inventor(s):Gediminas Brizgys, Eda Canales, Chien-Hung Chou, Michael Graupe, Randall L. Halcomb, Yunfeng Eric Hu, Scott E. Lazerwith, John O. Link, Qi Liu, Yafan Lu, Roland D. SAITO, Scott D. Schroeder, John R. SOMOZA, Winston C. Tse, Jennifer R. Zhang
Assignee: Gilead Sciences Inc
Application Number:US14/771,779
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,951,043

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc SUNLENCA lenacapavir sodium SOLUTION;SUBCUTANEOUS 215973-001 Dec 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION ⤷  Start Trial
Gilead Sciences Inc YEZTUGO lenacapavir sodium SOLUTION;SUBCUTANEOUS 220018-001 Jun 18, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION ⤷  Start Trial
Gilead Sciences Inc BIXLENVO bictegravir sodium; lenacapavir sodium TABLET;ORAL 221104-001 Aug 27, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN ⤷  Start Trial
Gilead Sciences Inc BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) bictegravir sodium, lenacapavir sodium; lenacapavir sodium TABLET;ORAL 221443-001 Aug 27, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN ⤷  Start Trial
Gilead Sciences Inc SUNLENCA lenacapavir sodium TABLET;ORAL 215974-001 Dec 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION ⤷  Start Trial
Gilead Sciences Inc SUNLENCA lenacapavir sodium TABLET;ORAL 215974-001 Dec 22, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN ⤷  Start Trial
Gilead Sciences Inc YEZTUGO lenacapavir sodium TABLET;ORAL 220020-001 Jun 18, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,951,043

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 094990 ⤷  Start Trial
Argentina 118856 ⤷  Start Trial
Australia 2014223973 ⤷  Start Trial
Australia 2016262671 ⤷  Start Trial
Australia 2018247348 ⤷  Start Trial
Brazil 112015021027 ⤷  Start Trial
Canada 2901502 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.